Sign in

CIK 0001601830

  • Large accelerated filer

RECURSION PHARMACEUTICALS, INC.

Sign in to watch
Ticker
RXRX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
464099738
Phone
+1 385-269-0203
Business address
41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
Former names
Recursion Pharmaceuticals, LLC
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$701,222
in 5 filings, $701K under 10b5-1 plans

Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2024-04-17 Secora Michael Chief Financial Officer Exercise or conversion 10b5-1 +37,500 $2.22 $83K 1,254,179
2024-04-17 Secora Michael Chief Financial Officer Sale 10b5-1 −23,124 $7.58 $175K 1,231,055
2024-04-17 Secora Michael Chief Financial Officer Exercise or conversion · Stock Option (Right to Buy) 10b5-1 −37,500 810,135
2024-04-16 Borgeson Blake Director Sale 10b5-1 −11,447 $7.66 $88K 7,229,861
2024-04-16 Secora Michael Chief Financial Officer Exercise or conversion 10b5-1 +37,500 $2.22 $83K 1,241,679
2024-04-16 Secora Michael Chief Financial Officer Sale 10b5-1 −25,000 $7.67 $192K 1,216,679
2024-04-16 Secora Michael Chief Financial Officer Exercise or conversion · Stock Option (Right to Buy) 10b5-1 −37,500 847,635
2024-04-04 Gibson Christopher Chief Executive Officer Sale 10b5-1 −40,000 $9.02 $361K 938,524
2024-04-04 Gibson Christopher Chief Executive Officer Conversion 10b5-1 +25,000 25,000
2024-04-04 Gibson Christopher Chief Executive Officer Sale 10b5-1 −25,000 $9.02 $226K 0
2024-04-04 Gibson Christopher Chief Executive Officer Conversion · Class B Common Stock 10b5-1 −25,000 486,000
2024-04-03 Gibson Christopher Chief Executive Officer Gift 10b5-1 −25,000 1,018,524
2024-04-03 Gibson Christopher Chief Executive Officer Sale 10b5-1 −40,000 $8.84 $354K 978,524
2024-04-03 Gibson Christopher Chief Executive Officer Conversion 10b5-1 +25,000 25,000
2024-04-03 Gibson Christopher Chief Executive Officer Sale 10b5-1 −25,000 $8.84 $221K 0
2024-04-03 Gibson Christopher Chief Executive Officer Conversion · Class B Common Stock 10b5-1 −25,000 67,875
2024-04-02 Borgeson Blake Director Sale 10b5-1 −11,447 $8.82 $101K 7,241,308
2024-04-01 Li Dean Y Director Grant or award +1,267 59,089
2024-04-01 CHAVEZ R. MARTIN Director Grant or award +2,001 60,078
2024-04-01 Dar Zavain Director Grant or award +1,467 89,056

Page 21 of 41 · 805 trades